Abstracts Archive - Page 1465 of 2607 - ACR Meeting Abstracts

Abstract Number: 1166 • 2017 ACR/ARHP Annual Meeting
Systemic Degos Disease: Long Term Survival on Combined Therapy with Eculizumab and Treprostinil
Lee S. Shapiro^1,2, Jessica Farrell^1,2,3, Roberta Lukasiewicz^1,2, Peter A. Merkel⁴, Douglas Rosing⁵, Manfred Boehm⁶, Axia Toledo-Garcia¹, Maria Karas⁷, Maria DeSancho⁸, Harry McCoy⁹, Michael Marmulstein¹⁰ and Scott Beegle¹¹, ¹The Center for Rheumatology, Albany, NY, ²Steffens Scleroderma Center, Albany, NY, ³Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, ⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, MN, ⁵Cardiovascular Pulmonary Branch, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, ⁶Center for Molecular Medicine, NHLBI/ NIH, Bethesda, MD, ⁷Division of Cardiology/Department of Medicine,, Weill Cornell Medical College, New York, NY, ⁸Weill Cornell Medical Center, New York, NY, ⁹Blue Ridge Cancer Care, Blacksburg, VA, ¹⁰Albany Associates in Cardiology, Albany, NY, ¹¹Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, NY
Background/Purpose: Degos disease (Malignant Atrophic Papulosis) is a thrombotic microvasculopathy of complement activation, endothelial cell injury and progressive microvascular obliteration. Lesions are marked by vascular…
Abstract Number: 1167 • 2017 ACR/ARHP Annual Meeting
Phenotypical Features of Patients with Rheumatologic Manifestations of Common Variable Immunodeficiency
MARIA GUTIERREZ¹, Kathleen E. Sullivan², Ramsay Fuleihan³ and Clifton O. Bingham III⁴, ¹Pediatrics, Johns Hopkins University, BALTIMORE, MD, ²Pediatrics, University of Pennsylvania, Philadelphia, PA, ³Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Patients with common variable immunodeficiency (CVID) have a higher incidence of rheumatologic disorders. To delineate this clinical association, we investigated the phenotypical features of…
Abstract Number: 1168 • 2017 ACR/ARHP Annual Meeting
Eosinophilic Fasciitis: Baseline Retrospective Evaluation of Clinical Characteristics and Prognosis in a Cohort of 83 Patients
Robert L. Mango¹, Kubra Bugdayli², Cynthia S. Crowson³, Margot S. Peters⁴, Lisa A. Drage⁵, Julia S. Lehman⁴ and Vaidehi Chowdhary⁶, ¹Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Pathology and Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ⁵Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ⁶Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Eosinophilic fasciitis (EF) is a rare disease and there have been few published series that include clinical, pathological and serological data. These studies have…
Abstract Number: 1169 • 2017 ACR/ARHP Annual Meeting
Rapid Improvement with Tocilizumab in Refractory and Severe Uveitic Cystoid Macular Edema
Nuria Vegas-Revenga¹, Vanesa Calvo-Río¹, Natalia Palmou-Fontana¹, Marina Mesquida², Alfredo Adan², M. Victoria Hernández², Emma Beltrán³, Elia Valls Pascual⁴, David Diaz-Valle⁵, Gisela Díaz-Cordovés⁶, Maria Luisa Hernández- Grafella⁷, Lucia Martínez- Costa⁷, Inmaculada Calvo⁸, Antonio Atanes⁹, Luis Francisco Linares¹⁰, Consuelo Modesto¹¹, Elena Aurrecoechea¹², Miguel Cordero-Coma¹³, Rosalía Demetrio-Pablo¹, Carlos Fernández-Díaz¹⁴, Lucia C. Domínguez-Casas¹⁴, José Luis Martín-Varillas¹⁴, Belén Atienza-Mateo¹⁴, Jose L. Hernández¹⁵, Miguel Angel González-Gay¹⁴ and Ricardo Blanco¹⁴, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ³Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁵Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ⁶Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ⁷Ophthalmology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁸Hospital Universitario i Politecnico La Fe. Valencia. Spain, Valencia, Spain, ⁹Rheumatology, Complejo Hospitalario Universitario A Coruña (CHUAC). Spain, A Coruna, Spain, ¹⁰Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹¹Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain, ¹²Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ¹³Ophthalmology, Hospital de León. Spain, León, Spain, ¹⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁵Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: In uveitis, remission-inducing therapy with even more vigor than does rheumatology is mandatory. Since the eye is so much less forgiving of chronic inflammation…
Abstract Number: 1170 • 2017 ACR/ARHP Annual Meeting
High Output Flow Cytometry Array Classifies Subjects with Uveitis Due to Behcet’s Disease and Sarcoidosis
Johannes Nowatzky¹, Ezra Resnick², Julia Manasson³, Cristy Stagnar¹ and Olivier Manches⁴, ¹Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ²Google Inc., New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴EFS Rhône-Alpes-Auvergne "Immunobiology and Immunotherapy in Chronic Diseases", INSERM - French National Institute of Health and Medical Research, Grenoble, France
Background/Purpose: The information content of multi-parametric flow cytometry-based immune-phenotyping experiments is routinely underexploited given the paucity of adequate tools and strategies for large-scale unbiased data…
Abstract Number: 1171 • 2017 ACR/ARHP Annual Meeting
Mycophenolate Mofetil May Improve Interstitial Pneumonia with Autoimmune Features
Sara S. McCoy¹, Zubin Mukadam², Keith C. Meyer³, Emmanuel Sampene⁴, Jeffrey P. Kanne⁵, Christopher A. Meyer⁵, Maria D. Martin⁵, Scott W. Aesif⁶, Laurie Rice⁷ and Christie M. Bartels⁸, ¹Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²PULMONARY & CRITICAL CARE, University of Wisconsin School of Medicine and Public Health, madison, WI, ³PULMONARY & CRITICAL CARE, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, madison, WI, ⁷Critical Care Medicine, SSM Health Dean Medical Group, madison, WI, ⁸Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: To assess the efficacy of mycophenolate mofetil (MMF) in treatment of adult patients with interstitial pneumonia with autoimmune features (IPAF). Methods: A retrospective medical…
Abstract Number: 1172 • 2017 ACR/ARHP Annual Meeting
Utility of Interstitial Pneumonia with Autoimmune Features (IPAF) Proposed Criteria in the Classification of Patients with CTD-Associated Interstitial Lung Disease in a Single Centre
Fredeswinda I. Romero-Bueno¹, Ana Sofía Pozo², Maria Jesus Rodriguez-Nieto³, Maria José Martinez-Becerra⁴, Gabriel Herrero-Beaumont⁵ and Olga Sanchez-Pernaute¹, ¹Section for Autoimmune Diseases, Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ²Faculty of Medicine, Autonoma University of Madrid, Madrid, Spain, ³Pulmonary Medicine, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁴Immunology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁵Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain
Background/Purpose: The term interstitial pneumonia with autoimmune features (IPAF) has recently been proposed to identify those patients with ILD and clinical and/or serological autoimmune manifestations…
Abstract Number: 1173 • 2017 ACR/ARHP Annual Meeting
Rheumatic Immune Related Adverse Events Due to Programmed Cell Death Protein 1 (PD-1) Inhibition for Cancer: Comprehensive Analysis of a Whole Cancer Cohort
David Liew^1,2,3, Jessica Leung¹, Bonnia Liu¹, Jonathan Cebon^3,4, Albert Frauman^2,3 and Russell Buchanan¹, ¹Department of Rheumatology, Austin Health, Melbourne, Australia, ²Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Australia, ³Department of Medicine, University of Melbourne, Melbourne, Australia, ⁴Olivia Newton-John Cancer Wellness & Research Centre, Melbourne, Australia
Background/Purpose: Immune checkpoint therapy with programmed cell death protein 1 (PD-1) inhibitors has led to significant survival benefits in the treatment of multiple cancers. This…
Abstract Number: 1174 • 2017 ACR/ARHP Annual Meeting
Which Definition Should be Used to Determine Colchicine Resistance in Patients with Familial Mediterranean Fever?
Abdulsamet Erden¹, Ezgi Deniz Batu², Alper Sari³, Hafize Emine Sonmez⁴, Berkan Armagan³, Selcan Demir⁴, Esra Fırat⁵, Yelda Bilginer⁶, Sule Apras Bilgen¹, Omer Karadag¹, Umut Kalyoncu¹, Sedat Kiraz¹, Ihsan Ertenli¹, Seza Ozen⁷ and Ali Akdogan³, ¹Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Pediatrics, Divison of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ³Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Department of Pediatrics, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁶Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Colchicine is the main therapy for familial Mediterranean fever (FMF); however, around 5-10% of FMF patients are colchicine-resistant. Currently there is no standard and…
Abstract Number: 1175 • 2017 ACR/ARHP Annual Meeting
Rituximab for Idiopathic and IgG4-Related Retroperitoneal Fibrosis
Rachel Wallwork¹, Zachary S. Wallace², Cory A. Perugino³, Amita Sharma⁴ and John H. Stone⁵, ¹Department of Medicine, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ⁴Department of Radiology, Massachusetts General Hospital, Boston, MA, ⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Rituximab for Idiopathic and IgG4-Related Retroperitoneal FibrosisBackground/Purpose: Untreated retroperitoneal fibrosis (RPF) can lead to chronic back and flank pain and/or renal failure. The mainstay of…
Abstract Number: 1176 • 2017 ACR/ARHP Annual Meeting
A Randomized, Open-Label, Dose-Ranging Study of Oral Delayed Release Prednisone in Patients with Untreated Polymyalgia Rheumatica
Jasvinder A. Singh¹ and Lee S. Simon², ¹Medicine, University of Alabama at Birmingham, Alabama, AL, ²SDG LLC Consulting, West Newton, MA
Background/Purpose: Polymyalgia rheumatica (PMR) is a common condition of unknown etiology with a lifetime risk of 2.43% in women and 1.66% in men.1 PMR is…
Abstract Number: 1177 • 2017 ACR/ARHP Annual Meeting
Airway Findings in Patients with Relapsing Polychondritis
Marcela A. Ferrada¹, James D. Katz², Keith A. Sikora³, Allen Clint⁴, Jeff Kim⁴, Wendy Goodspeed⁴, Robert Colbert⁵, Marcus Chen⁶, Arlene Sirajuddin⁴ and Peter C. Grayson², ¹NIAMS, National Institues of Health, Bethesda, MD, ²National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ³Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵NIAMS/NIH, Bethesda, MD, ⁶NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare multiorgan disease. Involvement of the upper and lower airways is associated with significant morbidity and mortality. Isolated airway…
Abstract Number: 1178 • 2017 ACR/ARHP Annual Meeting
Sympathetic Joint Effusion in an Urban Hospital
Jessica L. Barlow¹ and Irene J. Tan^2,3, ¹Internal Medicine, Temple University Hospital, Philadelphia, PA, ²Temple University Hospital, Philadelphia, PA, ³Section of Rheumatology, Temple University Lewis Katz School of Medicine, Philadelphia, PA
Background/Purpose: Sympathetic joint effusion (SJE) or sympathetic synovial effusion (SSE) is a rheumatologic entity that has not been well defined in the medical literature. It…
Abstract Number: 1179 • 2017 ACR/ARHP Annual Meeting
A Multi-Organ Inflammatory Condition with Features of Idiopathic Multicentric Castleman’s Disease and IgG4-Related Disease: An Unrecognized Mimicker of IgG4-RD
Zachary S. Wallace¹, Yasuharu Sato², Kazuichi Okazaki³, Judith Ferry⁴, Hisanori Umehara⁵, Aliyah Sohani⁶, Mitsuhiro Kawano⁷, Nancy Harris⁶, Yoshiya Tanaka⁸, Cory A. Perugino⁹, Satoshi Kubo¹⁰, James Stone⁴, Robert Colvin⁴, Tsutomu Chiba¹¹, John H. Stone¹² and Yoh Zen¹³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Pathology, Okayama University Graduate School of Medicine, Okayama, Japan, ³Department of Gastroenterology and Hepatology, Kansai Medical University, Osaka, Japan, ⁴Department of Pathology, Massachusetts General Hospital, Boston, MA, ⁵Kyoto University, Kyoto, Japan, ⁶Massachusetts General Hospital, Boston, MA, ⁷Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan, ⁹Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ¹⁰The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹¹Department of Gastroenterology and Hepatology, Kyoto University, Kyoto, MA, ¹²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹³Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Some of clinical features of the plasma cell type of human herpesvirus-8-negative multicentric Castleman’s disease (idiopathic MCD or iMCD) are similar to those of…
Abstract Number: 1180 • 2017 ACR/ARHP Annual Meeting
Multicenter Study on the Rate of Renal Function Deterioration in IgG4-Related Tubulointerstitial Nephritis
Mitsuhiro Kawano¹, Ichiro Mizushima², Takahiro Matsunaga¹, Kazunori Yamada³, Satoshi Hara¹, Hiroshi Fujii¹, Takako Saeki⁴, Yoshinori Taniguchi⁵ and Hitoshi Nakashima⁶, ¹Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, ²Kanazawa University Hospital, Kanazawa, Japan, ³Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ⁴Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁵Department of Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Kochi, Japan, ⁶Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
Background/Purpose: Only a few reports have focused on the rate of renal function deterioration in IgG4-related tubulointerstitial nephritis (IgG4-TIN). Some cases show acute or progressive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].